История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $1.7B | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B | $1.0B | $1.2B | $1.1B | $903M | $746M | $628M | $619M | $433M | $576M | $576M | $390M | $187M | $178M | $327M | $241M |
| Валовая прибыль | $1.4B | $1.3B | $1.3B | $1.4B | $894M | $976M | $860M | $991M | $918M | $749M | $614M | $489M | $443M | $299M | $265M | $405M | $262M | $134M | $129M | $283M | $200M |
| Валовая маржа % | 84.6% | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% | 77.9% | 71.6% | 69.0% | 46.1% | 70.4% | 67.3% | 72.0% | 72.3% | 86.7% | 83.1% |
| Операционная прибыль (EBIT) | $117M | $254M | $421M | $414M | ($6M) | $98M | ($112M) | ($175M) | ($99M) | ($148M) | ($209M) | ($224M) | ($87M) | $16M | $82M | $82M | ($88M) | ($46M) | ($43M) | $135M | ($3M) |
| Операционная маржа % | 7.0% | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% | -35.7% | -14.1% | 3.6% | 14.2% | 14.2% | -22.6% | -24.4% | -24.1% | 41.3% | -1.2% |
| Чистая прибыль | $66M | $242M | $367M | $356M | ($158M) | ($48M) | ($111M) | ($197M) | ($139M) | ($158M) | ($208M) | ($227M) | ($30M) | $18M | $25M | $25M | ($114M) | ($46M) | ($40M) | $131M | $167M |
| Чистая маржа % | 4.0% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% | -36.1% | -4.9% | 4.1% | 4.3% | 4.3% | -29.1% | -24.4% | -22.2% | 39.9% | 69.4% |
| EBITDA | $218M | $331M | $495M | $519M | $60M | $178M | ($6M) | ($103M) | ($8M) | ($33M) | ($105M) | ($125M) | $97M | $66M | $115M | $158M | ($38M) | ($35M) | ($14M) | $155M | $16M |
| Прибыль на акцию (EPS) | $0.39 | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.30 | $-0.70 | $-1.25 | $-0.90 | $-1.03 | $-1.38 | $-1.52 | $-0.21 | $0.12 | $0.18 | $0.18 | $-1.19 | $-0.48 | $-0.42 | $1.36 | $1.62 |
| Акции в обращении (M) | 167M | 169M | 169M | 170M | 164M | 161M | 159M | 157M | 155M | 153M | 151M | 149M | 145M | 145M | 137M | 137M | 96M | 96M | 95M | 96M | 103M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике ALKS. /companies/us/ALKS
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms